Risperidone

Generic Name
Risperidone
Brand Names
Perseris, Risperdal, Rykindo, Uzedy, Okedi
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
106266-06-2
Unique Ingredient Identifier
L6UH7ZF8HC
Background

Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).

Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.

Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets which may responsible for some of its undesirable effects.

Indication

Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.

Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.

Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.

Associated Conditions
Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
Associated Therapies
-

A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia

Phase 3
Completed
Conditions
First Posted Date
2005-11-15
Last Posted Date
2010-12-03
Lead Sponsor
Janssen, LP
Target Recruit Count
458
Registration Number
NCT00253136

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia

First Posted Date
2005-11-15
Last Posted Date
2010-12-03
Lead Sponsor
Janssen, LP
Target Recruit Count
626
Registration Number
NCT00253123

A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder

First Posted Date
2005-11-15
Last Posted Date
2012-08-06
Lead Sponsor
Janssen, LP
Target Recruit Count
396
Registration Number
NCT00253110

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia

Phase 3
Completed
Conditions
First Posted Date
2005-11-07
Last Posted Date
2011-02-11
Lead Sponsor
Janssen, LP
Target Recruit Count
1579
Registration Number
NCT00249119

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

First Posted Date
2005-11-07
Last Posted Date
2011-01-14
Lead Sponsor
Janssen Pharmaceutica N.V., Belgium
Target Recruit Count
349
Registration Number
NCT00249145

A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia

Phase 3
Completed
Conditions
First Posted Date
2005-11-07
Last Posted Date
2011-02-11
Lead Sponsor
Janssen, LP
Target Recruit Count
523
Registration Number
NCT00249132

A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

First Posted Date
2005-11-07
Last Posted Date
2010-11-19
Lead Sponsor
Janssen-Cilag Pty Ltd
Target Recruit Count
344
Registration Number
NCT00249158
© Copyright 2024. All Rights Reserved by MedPath